November 9, 2021

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease

TOKYO, Nov 9, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led…

March 16, 2021

Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer’s Disease by Dian-Tu

TOKYO, Mar 16, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was…